John R. North, Ph.D., President & Chief Executive Officer
Dr. North most recently served as Sr. Vice President, Scientific Affairs and Chief Scientific Officer of QLT, Inc. Prior to joining QLT, Dr. North was Managing Director of Monotech Laboratories Ltd., Biotechnology Consultant at PA Technology Ltd. and spent 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, most recently as Head of Exploratory Development at Ipsen International in the U.K. Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.

Oreola Donini, Ph.D., Senior Director, Preclinical R&D
Dr. Donini has 10 years experience in drug discovery, optimization and development and has lead the discovery, selection and advancement of Inimex' lead drug candidate, IMX942. Prior to joining Inimex, Dr. Donini was involved in drug discovery and development at Kinetek Pharmaceuticals, managing a key program with an external partner, as well as initiating and managing a team providing informatics analysis and support to the company at large. Dr. Donini received her PhD in Chemistry from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California, San Francisco.

Martin (Marty) McConnell, C.A., Chief Financial Officer
For the past five years Marty has worked with emerging high tech and Biotech companies as part-time CFO focused on strategic financial issues. For the prior 18 years he was CFO for two midsize public (TSX, Nasdaq) Canadian high tech companies, from 1993 to 2002 with Spectrum Signal Processing Inc. and from 1985 to 1993 at Epic Data International Inc. Mr. McConnell holds a B. Comm. from the University of British Columbia and is a Chartered Accountant.